$3.34
0.89% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
US14888D2080
Symbol
CSCI
Sector
Industry

Catalyst Biosciences, Inc. Stock price

$3.34
+0.00 0.00% 1M
+0.67 24.86% 6M
+0.57 20.58% YTD
-1.21 26.59% 1Y
-15.72 82.48% 3Y
-80.16 96.00% 5Y
-2,696.66 99.88% 10Y
-332,652.32 100.00% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
-0.03 0.89%
ISIN
US14888D2080
Symbol
CSCI
Sector
Industry

Key metrics

Basic
Market capitalization
$10.5m
Enterprise Value
$-1.0m
Net debt
$-11.5m
Cash
$13.8m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | -
P/S
1.16 | -
EV/Sales
negative | -
EV/FCF
0.07
P/B
1.04
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.00% | 0.00%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.00% | 0.00%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$9.0m | -
EBITDA
$-18.2m | -
EBIT
$-20.1m
Net Income
$-17.6m | -
Free Cash Flow
$-13.9m
Growth (TTM | estimate)
Revenue
103.84% | -
EBITDA
-17.66% | -
EBIT
-28.43%
Net Income
-28.08% | -
Free Cash Flow
19.80%
Margin (TTM | estimate)
Gross
47.26%
EBITDA
-201.38% | -
EBIT
-222.29%
Net
-194.50% | -
Free Cash Flow
-154.25%
Financial Health
Equity Ratio
37.53%
Return on Equity
-116.32%
ROCE
-83.36%
ROIC
-166.18%
Debt/Equity
0.22
More
EPS
$-5.58
FCF per Share
$-4.42
Short interest
0.65%
Employees
-
Rev per Employee
-
Show more

Is Catalyst Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Catalyst Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Catalyst Biosciences, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Catalyst Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Catalyst Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9.03 9.03
104% 104%
100%
- Direct Costs 4.76 4.76
250% 250%
53%
4.27 4.27
39% 39%
47%
- Selling and Administrative Expenses 12 12
43% 43%
128%
- Research and Development Expense 8.37 8.37
21% 21%
93%
-18 -18
18% 18%
-201%
- Depreciation and Amortization 1.89 1.89
1,012% 1,012%
21%
EBIT (Operating Income) EBIT -20 -20
28% 28%
-222%
Net Profit -18 -18
28% 28%
-194%

In millions USD.

Don't miss a Thing! We will send you all news about Catalyst Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalyst Biosciences, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
TORONTO, ONTARIO, May 26, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today confirmed that its Board of Directors has received a letter from Goodwood Fund and Puccetti Funds Management Inc.(“Goo...
Neutral
GlobeNewsWire
about 2 months ago
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the quarter with US$13.8 million in cash Advancing Phase 2 clinical trial with Avenanthramide product Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief E...
Neutral
GlobeNewsWire
3 months ago
Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward; Company ended the quarter with US$16.4 million in cash Revenues of US$9.6M vs US$7.1M in 2023, a 35.2% increase YOY TORONTO, ONTARIO, April 09, 2025 (GLOBE NEW...
More Catalyst Biosciences, Inc. News

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on August 20, 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Anna Biehn
Founded 1997
Website www.cosciensbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today